To include your compound in the COVID-19 Resource Center, submit it here.

AT-406: Phase I data

An open-label, U.S. Phase I trial in 29 AML patients showed that once-daily 100, 200, 300 or 400 mg

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE